![Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/341170479/figure/fig2/AS:962781394255883@1606556380401/Kaplan-Meier-curves-for-overall-survival-The-median-overall-survival-was-180months-95.png)
Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram
![Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram](https://www.researchgate.net/publication/5872888/figure/fig1/AS:601697068015627@1520467168720/Overall-survival-curve-Median-overall-survival-time-was-82-months-The-initial-date-of.png)
Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram
![Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with](https://mma.prnewswire.com/media/584686/Overall_Survival_Pancreas_Graph_Infographic.jpg?w=200)
Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with
![VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer | 2 Minute Medicine VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer | 2 Minute Medicine](https://www.2minutemedicine.com/wp-content/uploads/2023/08/2MM_08.22.2023_1_Alisha_Lung.jpg)
VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer | 2 Minute Medicine
![Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of](https://ars.els-cdn.com/content/image/1-s2.0-S0959804914008727-fx6.jpg)
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
![NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X](https://pbs.twimg.com/media/CPyBkyOUEAEiJyZ.png)
NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X
![Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-022-01637-7/MediaObjects/41375_2022_1637_Fig1_HTML.png)
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia
![Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-022-01845-z/MediaObjects/41416_2022_1845_Fig3_HTML.png)
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
![Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population](https://www.mdpi.com/biology/biology-10-00890/article_deploy/html/images/biology-10-00890-g001.png)
Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
![Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis | SpringerLink Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-020-03451-6/MediaObjects/11060_2020_3451_Fig4_HTML.png)
Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis | SpringerLink
![NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months](https://pbs.twimg.com/media/FJf6WueVIAMWHvU.jpg)
NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months
![Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma | Anticancer Research Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/11/6303/F2.large.jpg)